Results 1 to 10 of about 485,092 (339)

Repurposed anti-cancer epidermal growth factor receptor inhibitors: mechanisms of neuroprotective effects in Alzheimer’s disease

Neural Regeneration Research, 2022
Numerous molecular mechanisms are being examined in an attempt to discover disease-modifying drugs to slow down the underlying neurodegeneration in Alzheimer’s disease.
Heba M Mansour, Hala M Fawzy, Aiman S El-Khatib, Mahmoud M Khattab   +3 more
doaj   +1 more source

Epidermal growth factor receptor signaling [PDF]

Current Biology, 2001
Inhibitory signaling is an important way of fine tuning EGFR activity to enable a cell to discriminate between short and prolonged exposure to signaling molecules. Over the last few years a number of different mechanisms have been shown to abrogate receptor activity (Fig. 3Fig. 3). First, inhibitory signaling molecules are expressed in response to EGFR
Christian Klämbt, Sven Bogdan
openaire   +3 more sources

An EGFR T790M-mutated lung adenocarcinoma undergoing large-cell neuroendocrine carcinoma transformation after osimertinib therapy: a case report

Journal of Medical Case Reports, 2020
Background Osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor, is selective for both epidermal growth factor receptor tyrosine kinase inhibitor–sensitizing and T790M resistance mutations.
Shinichi Miyazaki, Yasumasa Kuno, Shunsaku Hayai, Ryo Teramachi, Ryo Yamashita, Yusuke Saito, Kosuke Higuchi, Yoshiharu Nara, Takuya Ikeda   +8 more
doaj   +1 more source

Targeting the epidermal growth factor receptor [PDF]

British Journal of Cancer, 2004
The epidermal growth factor receptor (EGFR) is a member of the erbB family of tyrosine kinase receptors (RTK). The EGFR is involved in cell proliferation, metastasis and angiogenesis, and is expressed in a large proportion of epithelial tumours. The two main classes of EGFR inhibitors in clinical trials are the RTK inhibitors and the monoclonal ...
Bassel F. El-Rayes, Patricia LoRusso
openaire   +3 more sources

Structure-Activity Relationship of Indole-Tethered Pyrimidine Derivatives that Concurrently Inhibit Epidermal Growth Factor Receptor and Other Angiokinases. [PDF]

PLoS ONE, 2015
Antiangiogenic agents have been widely investigated in combination with standard chemotherapy or targeted cancer agents for better management of advanced cancers.
Jiho Song, Jakyung Yoo, Ara Kwon, Doran Kim, Hong Khanh Nguyen, Bong-Yong Lee, Wonhee Suh, Kyung Hoon Min   +7 more
doaj   +1 more source

Epidermal Growth Factor Receptor immunohistochemical expression in hepatocellular carcinoma without Epidermal Growth Factor Receptor exons 18–21 mutations

Romanian Journal of Internal Medicine, 2022
Introduction: EGFR targeted therapies, have been proved beneficial for patients with HCC, nevertheless additional research on EGFR immunoexpresion and EGFR mutations is still needed, especially in population in which it has not been done yet.
Nikolova Dafina, Trajkovska Meri, Trpcevska Emilija Nikolovska, Eftimov Aleksandar, Jovanovik Rubens, Janevska Vesna   +5 more
doaj   +1 more source

The epidermal growth factor receptor conundrum [PDF]

Cancer, 2010
Soluble epidermal growth factor receptor (sEGFR), a cell surface and serum protein derived from an alternately spliced human EGFR transcript, is recognized by 2 therapeutic antibodies approved by the US Food and Drug Administration: cetuximab and panitumumab.
Jason A. Wilken, Andre T. Baron, Nita J. Maihle   +2 more
openaire   +3 more sources

Resistance mechanisms of epidermal growth factor receptor tyrosine kinase inhibitors in non‐small cell lung cancer patients: A meta‐analysis

Thoracic Cancer, 2021
Background Differences in the resistance mechanisms of epidermal growth factor receptor tyrosine kinase inhibitors in patients with non‐small cell lung cancer (NSCLC) harboring epidermal growth factor receptor mutations are unknown.
Nobuaki Kobayashi, Seigo Katakura, Chisato Kamimaki, Kohei Somekawa, Nobuhiko Fukuda, Katsushi Tanaka, Keisuke Watanabe, Nobuyuki Horita, Yu Hara, Hongmei Piao, Takeshi Kaneko   +10 more
doaj   +1 more source

Specific antibodies and sensitive immunoassays for the human epidermal growth factor receptors (HER2, HER3, and HER4)

Tumor Biology, 2017
The use of trastuzumab in patients with breast cancer that overexpresses human epidermal growth factor receptor 2 has significantly improved treatment outcomes.
Marianne Nordlund Broughton, Arne Westgaard, Elisabeth Paus, Miriam Øijordsbakken, Karoline J Henanger, Bjørn Naume, Trine Bjøro   +6 more
doaj   +1 more source

Strategies for monitoring and combating resistance to combination kinase inhibitors for cancer therapy

Genome Medicine, 2017
Targeted therapies such as kinase inhibitors and monoclonal antibodies have dramatically altered cancer care in recent decades. Although these targeted therapies have improved patient outcomes in several cancer types, resistance ultimately develops to ...
Leanne G. Ahronian, Ryan B. Corcoran
doaj   +1 more source